These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30013033)

  • 21. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity.
    Ru Q; Shang BY; Miao QF; Li L; Wu SY; Gao RJ; Zhen YS
    Eur J Pharm Sci; 2012 Nov; 47(4):781-9. PubMed ID: 22982402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
    Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
    BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.
    Du Y; Shang BY; Sheng WJ; Zhang SH; Li Y; Miao QF; Zhen YS
    Oncotarget; 2016 Sep; 7(36):58418-58434. PubMed ID: 27517152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Gelatinases-targeting scFv-based Fusion Protein Shows Enhanced Antitumour Activity with Endostar against Hepatoma.
    Gao R; Li L; Shang B; Zhao C; Sheng W; Li D
    Basic Clin Pharmacol Toxicol; 2015 Aug; 117(2):105-16. PubMed ID: 25615234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor efficacy of a recombinant EGFR-targeted fusion protein conjugate that induces telomere shortening and telomerase downregulation.
    Tao HY; He SM; Zhao CY; Wang Y; Sheng WJ; Zhen YS
    Int J Biol Macromol; 2023 Jan; 226():1088-1099. PubMed ID: 36435475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
    Liu H; Li L; Li XQ; Liu XJ; Zhen YS
    Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Binding capability of lidamycin apoprotein to human breast cancer detected by tissue microarrays].
    Cai L; Gao RJ; Guo XZ; Li Y; Zhen YS
    Yao Xue Xue Bao; 2010 May; 45(5):582-8. PubMed ID: 20931759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Optimization of the preparation process for fusion protein Fv-LDP that composes lidamycin apoprotein and single-chain Fv antibody directed against type IV collagenase].
    Gao RJ; Zhao CY; Li DD; Zhen YS
    Yao Xue Xue Bao; 2013 Oct; 48(10):1563-9. PubMed ID: 24417083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
    Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
    Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Recombinant and Reconstituted Novel Albumin-Lidamycin Conjugate Shows Lasting Tumor Imaging and Intensively Enhanced Therapeutic Efficacy.
    Li L; Hu L; Zhao CY; Zhang SH; Wang R; Li Y; Shao RG; Zhen YS
    Bioconjug Chem; 2018 Sep; 29(9):3104-3112. PubMed ID: 30105903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficient inhibition of B-cell lymphoma xenografts with a novel recombinant fusion protein: anti-CD20Fab-LDM.
    Xin C; Ye S; Ming Y; Shenghua Z; Qingfang M; Hongxing G; Xu S; Yuanfu X; Yuan Z; Dongmei F; Juanni L; Yingdai G; Lianfang J; Rongguang S; Zhenping Z; Jianxiang W; Tao C; Chunzheng Y; Dongsheng X; Yongsu Z
    Gene Ther; 2010 Oct; 17(10):1234-43. PubMed ID: 20463754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The recombinant EGFR/CD13 bi-targeted fusion protein induces apoptosis and blocks tube formation.
    Sheng W; Gong J; Jiang M; Zhen Y
    Oncol Rep; 2017 Dec; 38(6):3507-3514. PubMed ID: 29130101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
    Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
    Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.
    Solomon B; Hagekyriakou J; Trivett MK; Stacker SA; McArthur GA; Cullinane C
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):713-23. PubMed ID: 12573759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy.
    Xu J; Liu XJ; Li L; Zhang SH; Li Y; Gao RJ; Zhen YS
    Oncotarget; 2015 Sep; 6(28):26322-34. PubMed ID: 26314845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
    Zhou X; Qiu J; Wang Z; Huang N; Li X; Li Q; Zhang Y; Zhao C; Luo C; Zhang N; Teng X; Chen Z; Liu X; Yu X; Wu W; Wei YQ; Li J
    J Cancer Res Clin Oncol; 2012 Jul; 138(7):1081-90. PubMed ID: 22392077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.
    Berstad MB; Cheung LH; Berg K; Peng Q; Fremstedal AS; Patzke S; Rosenblum MG; Weyergang A
    Oncogene; 2015 Oct; 34(44):5582-92. PubMed ID: 25684137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity.
    Miao QF; Liu XY; Shang BY; Ouyang ZG; Zhen YS
    Anticancer Drugs; 2007 Feb; 18(2):127-37. PubMed ID: 17159599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin.
    Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y
    Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel multivalent (99m)Tc-labeled EG2-C4bpα antibody for targeting the epidermal growth factor receptor in tumor xenografts.
    Li C; Zhang Y; Wang L; Feng H; Xia X; Ma J; Yuan H; Gao B; Lan X
    Nucl Med Biol; 2015 Jun; 42(6):547-54. PubMed ID: 25779037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.